Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab

Hemolytic anemia and pure red cell aplasia (PRCA) after allogeneic hematopoietic stem cell transplantation (HSCT) have been reported to be mainly related to ABO‐incompatibility between donor and recipient. Autoimmune hemolytic anemia (AIHA) without ABO‐incompatibility has been also reported after allogeneic HSCT, especially with T‐cell depletion. However, optimal management of AIHA or PRCA remains unclear. A 54‐year‐old male with myelodysplastic syndrome (MDS) underwent haploidentical human leukocyte antigen‐mismatched HSCT using in vivo alemtuzumab and developed AIHA and PRCA simultaneously 15 months after transplantation, following the administration of cidofovir and probenecid for persistent cytomegalovirus (CMV) antigenemia and retinitis. AIHA was successfully treated with rituximab, and subsequently PRCA with cyclosporine without relapse of MDS or recurrence of CMV infection. The clinical course suggested that AIHA was mainly caused by humoral immune response, while PRCA was mainly caused by cell‐mediated immune response in this patient, although these immune responses might be related to each other. Am. J. Hematol., 2008. © 2007 Wiley‐Liss, Inc.

[1]  J. Thachil,et al.  Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia. , 2007, Leukemia research.

[2]  F. Noizat‐Pirenne,et al.  Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO‐incompatible allogeneic haematopoietic stem cell transplantation , 2007, Vox sanguinis.

[3]  W. Ouwehand,et al.  Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology , 2007, Annals of Hematology.

[4]  Y. Kanda,et al.  High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[5]  S. Ogawa,et al.  In Vivo Alemtuzumab Enables Haploidentical Human Leukocyte Antigen-Mismatched Hematopoietic Stem-Cell Transplantation Without Ex Vivo Graft Manipulation , 2005, Transplantation.

[6]  R. Putzulu,et al.  Rituximab for pure red cell aplasia after ABO‐mismatched allogeneic peripheral blood progenitor cell transplantation , 2005, Transfusion.

[7]  C. Craddock,et al.  Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.

[8]  S. Perrotta,et al.  Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. , 2003, Blood.

[9]  H. Prince,et al.  Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. , 2003, Blood.

[10]  B. Crowley,et al.  Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab , 2002, British journal of haematology.

[11]  C. Craddock,et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.

[12]  W. May,et al.  Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation , 2002, Bone Marrow Transplantation.

[13]  M. Boeckh,et al.  Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. , 2001, Blood.

[14]  D. Neuberg,et al.  Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. , 2000, Blood.

[15]  M. Laffan,et al.  Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant , 1997, Bone Marrow Transplantation.

[16]  J. Gottschall,et al.  Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. , 1996, Bone marrow transplantation.

[17]  K. Neftel,et al.  Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. , 1990, Blood.

[18]  I. Sniecinski,et al.  IMMUNOHEMATOLOGIC CONSEQUENCES OF MAJOR ABOMISMATCHED BONE MARROW TRANSPLANTATION , 1988, Transplantation.

[19]  P. Ness,et al.  Probenecid induced immune hemolytic anemia. , 1986, The Journal of rheumatology.

[20]  G. Garratty,et al.  Immune hemolytic anemia associated with probenecid. , 1985, American journal of clinical pathology.